CellFE

Executive Summary

CellFE is a private biotechnology company pioneering a microfluidics-based mechanoporation platform to address critical bottlenecks in cell therapy manufacturing. Traditional viral vector-based gene delivery methods are costly, limited in scalability, and pose safety risks. CellFE's non-viral intracellular delivery technology enables efficient, large-scale engineering of cells, such as CAR-T and TCR-T, without the drawbacks of viral methods. By integrating mechanoporation with microfluidic chip design, the company aims to reduce production costs and increase accessibility of advanced cell therapies. Founded in 2017 and headquartered in Alameda, California, CellFE is positioned to transform the manufacturing landscape for cell and gene therapies. CellFE's platform has the potential to unlock broader adoption of cell therapies by simplifying the supply chain and enabling consistent, high-throughput production. The company is currently advancing its technology through preclinical studies and seeking strategic partnerships to validate its approach in clinical settings. With the cell therapy market projected to grow significantly, CellFE's solution addresses a pressing need for scalable, cost-effective manufacturing. If successful, the company could become a key enabler for the next generation of gene-edited cell therapies, making treatments more affordable and accessible to patients worldwide.

Upcoming Catalysts (preview)

• Q2 2026Series B funding round70% success
• Q3 2026Partnership with a major cell therapy developer60% success
• Q4 2026Publication of preclinical proof-of-concept data80% success